Sugi Predict

Sugi Predict / Compounds / Methylparaben

Methylparaben

Methylparaben

SCHEMBL321534

COC(=O)c1ccc(O)cc1.COC(=O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 8/20 1.00
▸ CA2 P00918 8/20 1.00
▸ CA12 O43570 5/20 1.00
▸ CA7 P43166 5/20 1.00
▸ CA9 Q16790 5/20 1.00
▸ CA14 Q9ULX7 5/20 1.00
▸ ALDH1A1 P00352 4/20 0.69
▸ LMNA P02545 1/20 0.69
▸ GAA P10253 1/20 0.69
▸ TDP1 Q9NUW8 2/20 0.67
▸ TSHR P16473 2/20 0.62
▸ MAPT P10636 2/20 0.59
▸ ESR1 P03372 2/20 0.59
▸ XDH P47989 1/20 0.59
▸ ESR2 Q92731 1/20 0.59
▸ LOXL2 Q9Y4K0 1/20 0.57
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ CHRM1 P11229 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylparaben SCHEMBL4440 1.00 CA1 (1.00) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL48757 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL21274302 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL1699480 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL16029235 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL2810862 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL475867 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL8779118 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL6315862 0.98 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL31713879 0.98 CA1 (0.95) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105496801-A Nanostructured solid lipid carrier coating vitamin A palmitate and preparation method thereof SHANGHAI INST TECHNOLOGY 2016-04-20 — — CN claimed
WO-2024121113-A1 ADAMTS12 AS A TARGET MOLECULE FOR THE TREATMENT OF CHRONIC RENAL INSUFFICIENCY AND RENAL FIBROSIS RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) 2024-06-13 — — WO disclosed
US-20240165257-A1 ANTI-GUCY2C ANTIBODY AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2024-05-23 — — US disclosed
WO-2024094688-A1 ANTI-GUCY2C ANTIBODY AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2024-05-10 — — WO disclosed
US-11976131-B2 Humanized antibodies against PSMA HEIDELBERG PHARMA RESEARCH GMBH (DE) 2024-05-07 — — US disclosed
EP-4308169-A2 B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES Heidelberg Pharma Research GmbH (DE) 2024-01-24 — — EP disclosed
WO-2023247607-A1 FATP2 IN T CELLS AS A TARGET MOLECULE FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) 2023-12-28 — — WO disclosed
EP-4240424-A1 COMPOSITION COMPRISING A COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND ANTIBODY-AMATOXIN CONJUGATE FOR USE IN CANCER THERAPY Heidelberg Pharma Research GmbH (DE) 2023-09-13 — — EP disclosed
EP-4237078-A1 NKD2 AS TARGET FOR TREATING RENAL FIBROSIS Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) 2023-09-06 — — EP disclosed
US-20230250189-A1 Humanized Antibodies Against PSMA HEIDELBERG PHARMA RESEARCH GMBH (DE) 2023-08-10 — — US disclosed
WO-1995024124-A1 IMPROVED INSECTICIDE BAIT EMULSION COMPOSITION THE CLOROX COMPANY (US) 1995-09-14 — — WO disclosed
EP-0664790-A1 HYDROXY ALKYL AMIDES OF DICARBOXYLIC ACIDS AND THEIR USE IN COSMETIC COMPOSITIONS QUEST INTERNATIONAL B.V. (NL) 1995-08-02 — — EP disclosed
WO-1995013047-A1 DECOLORIZED CAROTENOID-CYCLODEXTRIN COMPLEXES SCHWARTZ JOEL L (US) 1995-05-18 — — WO disclosed
WO-1994007844-A1 HYDROXY ALKYL AMIDES OF DICARBOXYLIC ACIDS AND THEIR USE IN COSMETIC COMPOSITIONS QUEST INTERNATIONAL B.V. (NL) 1994-04-14 — — WO disclosed
EP-0558706-A1 COCKROACH BAIT FEEDING STIMULI. CLOROX CO (US) 1993-09-08 — — EP disclosed
WO-1993005651-A1 COCKROACH BAIT FEEDING STIMULI THE CLOROX COMPANY (US) 1993-04-01 — — WO disclosed
WO-1989010114-A1 COMPOSITION FOR PROMOTING HAIR GROWTH IN ANDROGENETIC ALOPECIA AND METHOD THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 1989-11-02 — — WO disclosed
EP-0296205-A4 METHOD AND COMPOSITION FOR HAIR GROWTH IN COMMON PATTERN BALDNESS. UNIV BOSTON (US) 1989-03-14 — — EP disclosed
EP-0296205-A1 METHOD AND COMPOSITION FOR HAIR GROWTH IN COMMON PATTERN BALDNESS TRUSTEES OF BOSTON UNIVERSITY (US) 1988-12-28 — — EP disclosed
WO-1988004931-A1 METHOD AND COMPOSITION FOR HAIR GROWTH IN COMMON PATTERN BALDNESS TRUSTEES OF BOSTON UNIVERSITY (US) 1988-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240165257-A1 ANTI-GUCY2C ANTIBODY AND USES THEREOF GUCY1B2, MTX2, GUCY1A2 CA1 2869/4885CA2 2010/4885CA12 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.